Update on Alzheimer drugs (donepezil)

Neurologist

Volumn 9, Issue 5, 2003, Pages 225-229

  Doody, Rachelle Smith ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Alzheimer disease; Donepezil; Treatment

Indexed keywords

CIMETIDINE; DIGOXIN; DONEPEZIL; PAROXETINE; PLACEBO; THEOPHYLLINE; WARFARIN;

ALZHEIMER DISEASE; ASTHENIA; BEHAVIOR DISORDER; CAREGIVER; CLINICAL TRIAL; COGNITION; COGNITIVE DEFECT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DIARRHEA; DOSE RESPONSE; DREAM; DRUG EFFICACY; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERANCE; FATIGUE; HUMAN; INSOMNIA; META ANALYSIS; MULTIINFARCT DEMENTIA; MUSCLE CRAMP; NAUSEA; NIGHTMARE; NURSING HOME; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SYNCOPE; VERTIGO;

ALZHEIMER DISEASE; ANIMALS; CHOLINESTERASE INHIBITORS; HUMANS; INDANS; PIPERIDINES;

EID: 0141704174     PISSN: 10747931     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.nrl.0000087723.53475.48     Document Type: Review

References (33)

1. Doody RS. Clinical benefits of a new piperidine-class Ache inhibitor. Eur Neuro-Psychopharmacol. 1999;9:S69-S77.
2. Guillozet AL, Smiley JF, Mash DC, et al. Butyrylcholinesterase in the life cycle of amyloid plaques. Gerontology. 1997;42:909-918.
3. Doody RS. Clinical profile of donepezil in the treatment of Alzheimer's Disease. Gerontology. 1999;45:23-32.
4. Sherman KA. Pharmacodynamics of oral E2020 and tacrine in humans: Novel approaches. In: Becker R, Giaccobini E, eds. Cholinergic Basis for Alzheimer Therapy. Boston: Birkhäuser; 1991;321-328.
5. Rogers SL, Doody RS, Mohs RC, et al. Donepezil improves cognition and global function in Alzheimer disease. Arch Inter Med. 1998;158:1021-1031.
6. Kasa P, Papp H, Kasa P. Donepezil dose-dependently inhibits acetylcholinesterase activity in various areas and in the presynaptic cholinergic and the postsynaptic cholinoceptive enzyme-positive structures in the human and rat brain. Neuroscience. 2000;101:89-100.
7. Rogers SL, Friedhoff LT. The efficacy and safety of donepezil in patients with Alzheimer's disease: results of a US multicentre, randomized, double-blind, placebo-controlled trial. Dementia. 1996;7:293-303.
8. Rogers SL, Farlow MD, Doody RS, et al. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Neurology. 1998;50:136-145.
9. Burns A, Rossor M, Hecker J, et al. The effects of donepezil in Alzheimer's disease: results from a multinational trial. Dement Geriat Cogn Disord. 1999;10:237-244.
10. Mohs RC, Doody RS, Morris JC, et al. A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients. Neurology. 2001;57:481-488.
11. Winblad B, Engedal K, Soininen H, et al. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Neurology. 2001;57:489-495.
12. Feldman H, Gauthier S, Hecker J, et al. A 24-week, double-blind, study of donepezil in moderate to severe Alzheimer's disease. Neurology. 2001;57:613-620.
13. Ferris MJ, ed. A multicenter evaluation of new treatment efficacy instruments for Alzheimer's Disease clinical trials. ADAD. 1997;11:s1-s91.
14. Berg L, Smith DS, Morris JC, et al. Mild senile dementia of the Alzheimer type: 3 longitudinal and cross-sectional assessment. Ann Neurol. 1990;28:648-652.
15. Tariot P, Cummings J, Katz I, et al. A randomized, double-blind, placebo-controlled study of the efficacy and safety of Donepezil in patients with Alzheimer's Disease in the nursing home setting. J Am Geriatrics Soc. 2001;49:1590-1599.
16. Cummings JL, Donohue JA, Brooks RL. The relationship between donepezil and behavioral disturbances in patients with Alzheimer's disease. J Geriat Psychiatry. 2000;8:134-140.
17. Weiner MF, Martin-Cook K, Foster BM. Effects of donepezil on emotional/behavioral symptoms in Alzheimer's disease patients. J Clin Psychiatry. 2000;61:487-492.
18. Shea C, MacKnight C, Rockwood K. Donepezil for treatment of dementia with Lewy bodies: a case series of nine patients. Int Psychogeriatr. 1998;10:229-238.
19. Lanctot KL, Herrmann N. Donepezil for behavioural disorders associated with Lewy bodies: a case series. Int J Geriat Psychiatry. 2000;15:338-345.
20. Greene YM, Tariot PN, Wishart H. A 12-week, open trial of donepezil hydrochloride in patients with multiple sclerosis and associated cognitive impairments. J Clin Psychopharmacol. 2000;20:350-356.
21. Taverni JP, Seliger G, Lichtman SW. Donepezil medated memory improvement in traumatic brain injury during post acute rehabilitation. Brain Injury. 1998;12:77-80.
22. Hoopes SP. Donepezil for Tourette's Disorder and ADHD. J Clin Psychopharmacol. [letter] 1999;19:381-382.
23. Wengel SP, Roccaforte WH, Burke WJ. Donepezil improves symptoms of delirium in dementia: implications for future research. J Geriat Psychiatry Neurol. 1998;11:159-161.
24. Burt T, Sachs GS, Demopulos C. Donepezil in treatment-resistant bipolar disorder. Biol Psychiatry. 1999;45:959-964.
25. Kishani PS, Sullivan JA, Walter BK. Cholinergic therapy for down's syndrome. Lancet. [letter] 1999;353:10643-1065.
26. Litvan I, Phipps M, Pharr VL, et al. Randomized placebo-controlled trial of donepezil in patients with progressive supranuclear palsy. Neurology. 2001;57:467-473.
27. Pratt RD, Perdomo CA, and the Donepezil 307 Study group. Donepezil improves cognition and global function in patients with vascular dementia: results form study 307, a 24-week, randomized, double blind, placebo-controlled trial. European Neurological Society, Berlin, Germany, June 22-26, 2002 (poster).
28. Pratt RD, Perdomo CA, and the Donepezil 308 VaD study group. Donepezil-treated patients with vascular dementia demonstrate cognitive and global benefits: results from study 308, a 24-week, randomized, double-blind, placebo-controlled trial. European Neurological Society, Berlin, Germany, June 22-26, 2002 (poster).
29. Karlawish JHT, Whitehouse PJ. Is the placebo control obsolete in a world after donepezil and vitamin E? Arch Neurol. 1998;55:1420-1424.
30. Doody RS, Dunn JK, Clark CM, et al. Chronic donepezil treatment is associated with slowed cognitive decline in Alzheimer's disease. Dement Geriat Cogn Disord. 2001;12:295-300.
31. Rogers SL, Doody RS, Pratt RD, et al. Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: final analysis of a US multicentre open-label study. Eur Neuro-Psychopharmacol. 2000;10:195-203.
32. Doody RS, Geldmacher DS, Gordon B, et al. Open-label, multicenter, phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer disease. Arch Neurol. 2001;58:427-433.
33. Carrier L. Donepezil and paroxetine: possible drug interaction. J Am Geriat Soc. [letter] 1999;47:1037.